NASDAQ:XENE - Xenon Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.40
  • Forecasted Upside: 42.67 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$30.42
▼ -0.48 (-1.55%)

This chart shows the closing price for XENE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xenon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XENE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XENE

Analyst Price Target is $43.40
▲ +42.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Xenon Pharmaceuticals in the last 3 months. The average price target is $43.40, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 42.67% upside from the last price of $30.42.

This chart shows the closing price for XENE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Xenon Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2022WedbushLower Price TargetOutperform$47.00 ➝ $41.00Low
3/2/2022William BlairReiterated RatingOutperformLow
3/2/2022WedbushReiterated RatingOutperformLow
11/11/2021SVB LeerinkBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $40.00High
10/28/2021Royal Bank of CanadaInitiated CoverageOutperform$43.00High
10/4/2021Needham & Company LLCBoost Price TargetBuy$25.00 ➝ $48.00High
10/4/2021GuggenheimBoost Price TargetBuy$30.00 ➝ $45.00High
5/13/2021SVB LeerinkReiterated RatingBuy$28.00High
3/5/2021William BlairReiterated RatingBuyLow
3/2/2021SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $28.00High
3/2/2021Needham & Company LLCBoost Price TargetBuy$22.00 ➝ $25.00High
2/25/2021William BlairReiterated RatingOutperformLow
10/2/2020SVB LeerinkInitiated CoverageOutperform$22.00High
8/13/2020Bloom BurtonReiterated RatingBuy$25.00Medium
7/20/2020Needham & Company LLCInitiated CoverageBuy$22.00High
5/31/2020Jefferies Financial GroupInitiated CoverageBuy$16.00 ➝ $23.00High
5/22/2020William BlairReiterated RatingBuyHigh
3/24/2020WedbushInitiated CoverageOutperform$23.00Low
1/8/2020William BlairInitiated CoverageOutperformHigh
9/20/2019GuggenheimInitiated CoverageBuy$25.00High
3/29/2019Stifel NicolausReiterated RatingBuy$21.00 ➝ $18.00High
8/10/2018Jefferies Financial GroupReiterated RatingBuy$16.00Low
8/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$9.00 ➝ $15.00High
3/22/2018Jefferies Financial GroupBoost Price TargetBuy$6.00Medium
3/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.00High
8/4/2017Jefferies Financial GroupSet Price TargetBuy$5.00Medium
(Data available from 6/30/2017 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/2/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/1/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/31/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/31/2022
  • 7 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/30/2022

Current Sentiment

  • 7 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Xenon Pharmaceuticals logo
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More

Today's Range

Now: $30.42
Low: $29.75
High: $31.06

50 Day Range

MA: $29.28
Low: $25.44
High: $34.70

52 Week Range

Now: $30.42
Low: $14.65
High: $36.42

Volume

385,657 shs

Average Volume

498,918 shs

Market Capitalization

$1.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Xenon Pharmaceuticals?

The following Wall Street analysts have issued research reports on Xenon Pharmaceuticals in the last year: Guggenheim, Needham & Company LLC, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TheStreet, Wedbush, and William Blair.
View the latest analyst ratings for XENE.

What is the current price target for Xenon Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Xenon Pharmaceuticals in the last year. Their average twelve-month price target is $43.40, suggesting a possible upside of 42.7%.
View the latest price targets for XENE.

What is the current consensus analyst rating for Xenon Pharmaceuticals?

Xenon Pharmaceuticals currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XENE will outperform the market and that investors should add to their positions of Xenon Pharmaceuticals.
View the latest ratings for XENE.

How do I contact Xenon Pharmaceuticals' investor relations team?

Xenon Pharmaceuticals' physical mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company's listed phone number is (604) 484-3300 and its investor relations email address is [email protected] The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. Learn More about contacing Xenon Pharmaceuticals investor relations.